Biotech


  • A man in a collared shirt poses for a photograph.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    David Altshuler, geneticist who helped transform Vertex, to retire next year

    Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”

    By Ben Fidler • Aug. 5, 2025
  • Stephane Bancel, Moderna
    Image attribution tooltip
    Chip Somodevilla / Staff via Getty Images
    Image attribution tooltip

    Let’s make a deal? Big Pharma execs express varying views on their M&A future

    Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

    By Aug. 5, 2025
  • rare disease ribbon Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Rare diseases

    As drug developers find promise in the rare diseases, deals and treatments are on the rise

    By PharmaVoice staff
  • A smiling portrait of Vinay Prasad, the director of CBER, set against a sparkling light background.
    Image attribution tooltip
    Retrieved from Vinay Prasad on May 08, 2025
    Image attribution tooltip

    Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

    Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

    By Ben Fidler • July 30, 2025
  • Wall Street
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech investing is down, but some VC firms are bucking the trend

    Discipline is the name of the game after a glut of over-investing burst the biotech bubble.

    By Alexandra Pecci • July 29, 2025
  • Keytruda, Merck
    Image attribution tooltip
    Permission granted by Merck & Co.
    Image attribution tooltip

    Could bispecifics unseat Keytruda from its oncology throne?

    Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

    By Kelly Bilodeau • July 28, 2025
  • Lab bench
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

    The studies are contributing preclinical advances for some of the world’s biggest blockbusters.

    By July 25, 2025
  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Who is Dr. George Tidmarsh, the new director of CDER?

    Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

    By Meagan Parrish and Michael Gibney • July 23, 2025
  • Chinese flag with lot of medical pills isolated on black background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA invites more data from abroad — with a wary eye on China

    The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.

    By July 16, 2025
  • stock numbers below a NYSE sign
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again

    The IPO market is a mixed bag in 2025, with some signs of life but several headwinds keeping activity relatively low.

    By July 15, 2025
  • measles texas
    Image attribution tooltip
    Jan Sonnenmair via Getty Images
    Image attribution tooltip

    Early measles drug R&D kicks into gear as U.S. records record outbreak

    Several companies have announced preclinical efforts to develop the first-ever measles treatment.

    By July 11, 2025
  • Laboratory bottles with blue content and a syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    First 90 Days

    As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

    Simone Steiner recently joined the French company to set the stage for launch.  

    By July 9, 2025
  • Button
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Is biopharma dealmaking getting hot again?

    With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.

    By July 8, 2025
  • Intravenous drip of medicine at the hospital
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The MEK effect on cancer — a slow and steady approach to drug resistance

    Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

    By Kelly Bilodeau • July 8, 2025
  • China flag
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    Can China sustain a surge in oncology drug innovation?

    The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.

    By Kelly Bilodeau • July 2, 2025
  • AI brain
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

    The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

    By July 1, 2025
  • A person in a business suit looks past two other people standing with their backs to the camera.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip

    CDC panel, newly remade by RFK Jr., questions vaccine evidence

    New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

    By Delilah Alvarado • June 26, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Grandbrothers via Getty Images
    Image attribution tooltip

    Biopharma is on edge about NIH funding cuts and what the future holds for research

    Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

    By June 26, 2025
  • Narcotic Brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After myriad failures, a new wave of ALS drugs approaches

    Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.

    By June 25, 2025
  • Mathai Mammen, CEO, Parabilis Medicines
    Image attribution tooltip
    Permission granted by Parabilis
    Image attribution tooltip
    Q&A

    How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

    J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

    By June 24, 2025
  • Highway Boston
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Biotech’s turning point: for every challenge, an opportunity in disguise

    As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.

    By June 20, 2025
  • diversity hands pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How a patient group tackled research diversity for one disease and triggered change for pharma

    A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

    By June 17, 2025
  • Syringes biotech
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can ‘reputational pull’ save biotech from pharma’s image problem?

    A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

    By June 12, 2025
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Pharma’s wins and losses in the budget bill

    Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

    By June 11, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    The biggest obesity deals of 2025 so far

    Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

    By June 9, 2025
  • Enhertu
    Image attribution tooltip
    Permission granted by Daiichi Sankyo
    Image attribution tooltip

    With ADCs on the rise, drugmakers embrace a new oncology pillar

    A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

    By June 6, 2025